The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
NETRF Annual Report 2019 looks at scientific milestones and educational innovations. It includes stories about some of the people who have supported us to fund more research projects than ever before and offer new ways to learn about NETs.
Results find delays in care and treatment, fear of exposure to COVID-19 The Neuroendocrine Tumor Research Foundation (NETRF) recently surveyed NET patients and caregivers about
Research to Advance Neuroendocrine Tumor Treatment The Neuroendocrine Tumor Research Foundation (NETRF) today announced $3.5 million in neuroendocrine tumor (NET) research grants to fund 12
Physicians discuss the basics of NET diagnosis, classification, and progression. Particular attention is paid to the frequency of misdiagnosis. Two patients share their stories of delayed NET diagnosis and treatment due to the misidentification of symptoms.
Neuroendocrine Tumor Research Foundation celebrates the halfway point of Spark Hope campaign. $5.3 million raised to date.
Neuroendocrine tumor podcast explores neuroendocrine tumors (NETS), featuring world-renowned NET specialists and patients living with neuroendocrine cancer.
Aretha Franklin was a trailblazer. She broke barriers as the first woman welcomed into the Rock and Roll Hall of Fame and as the indisputable
New grant explores precision drug delivery in NETs The American Association of Cancer Researchers (AACR) has awarded a NETRF-funded research grant to a Texas researcher
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET